UY30525A1 - Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos - Google Patents

Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos

Info

Publication number
UY30525A1
UY30525A1 UY30525A UY30525A UY30525A1 UY 30525 A1 UY30525 A1 UY 30525A1 UY 30525 A UY30525 A UY 30525A UY 30525 A UY30525 A UY 30525A UY 30525 A1 UY30525 A1 UY 30525A1
Authority
UY
Uruguay
Prior art keywords
pdgfr
directed
alfa
antibodies
agents whose
Prior art date
Application number
UY30525A
Other languages
English (en)
Inventor
David Charles Blakey
Sue A Cartlidge
Xiao-Dang Yang
Gadi Gazit-Bornstein
Jaspal Singh Kang
Naomi Laing
Ian Foltz
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY30525A1 publication Critical patent/UY30525A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen agentes de union dirigidos cuyo blanco es el antígeno PDGFR-alfa y usos de dichos agentes. De manera más específica, la invencion está relacionada con anticuerpos monoclonales completamente humanos cuyo blanco es el antígeno PDGFR-alfa y usos de dichos anticuerpos. Ciertos aspectos de la invencion se relacionan asimismo con hibridomas u otras líneas celulares que expresan dichos anticuerpos. Los anticuerpos y agentes de union dirigidos descritos son utiles como agentes de diagnostico y para el tratamiento de enfermedades asociadas con la actividad y/o la sobreexpresion del PDGFR-alfa.
UY30525A 2006-08-03 2007-08-03 Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos UY30525A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83564706P 2006-08-03 2006-08-03

Publications (1)

Publication Number Publication Date
UY30525A1 true UY30525A1 (es) 2008-02-29

Family

ID=39146823

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30525A UY30525A1 (es) 2006-08-03 2007-08-03 Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos

Country Status (24)

Country Link
US (3) US20090324601A1 (es)
EP (3) EP2049571B1 (es)
JP (1) JP5437804B2 (es)
KR (1) KR101531422B1 (es)
CN (2) CN101558082B (es)
AR (1) AR062268A1 (es)
AU (1) AU2007348940B2 (es)
BR (1) BRPI0715223A2 (es)
CA (1) CA2657898A1 (es)
CL (1) CL2007002225A1 (es)
DK (1) DK2049571T3 (es)
ES (1) ES2402380T3 (es)
HK (1) HK1128481A1 (es)
IL (2) IL196209A (es)
MX (2) MX2009001021A (es)
NO (1) NO20090069L (es)
NZ (2) NZ596381A (es)
PL (1) PL2049571T3 (es)
PT (1) PT2049571E (es)
SI (1) SI2049571T1 (es)
TW (1) TWI503329B (es)
UY (1) UY30525A1 (es)
WO (1) WO2008112003A2 (es)
ZA (1) ZA200900461B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
WO2008144345A2 (en) * 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
CA2718878A1 (en) * 2008-03-10 2009-09-17 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus
JP2013177317A (ja) * 2010-06-24 2013-09-09 Meneki Seibutsu Kenkyusho:Kk 抗ｐｄｇｆ受容体抗体
US8754195B2 (en) 2010-07-02 2014-06-17 Medimmune, Llc Antibody formulations
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
EP2771037B1 (en) * 2011-10-28 2016-08-03 Fredax AB Therapeutic agents and uses thereof
MX360141B (es) * 2012-02-17 2018-10-24 Seattle Genetics Inc Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
WO2013160359A1 (en) * 2012-04-24 2013-10-31 Thrombogenics N.V. Anti-pdgf-c antibodies
EP2877572B1 (en) 2012-07-24 2018-11-28 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9605074B2 (en) * 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
MX2015005874A (es) * 2012-11-09 2015-09-10 Pfizer Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
GB201318793D0 (en) * 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
KR102442738B1 (ko) 2013-11-19 2022-09-15 프레닥스 에이비 인간화된 안티 칼리크레인-2 항체
JP6883579B2 (ja) 2015-08-11 2021-06-09 ウーシー バイオロジクス（ケイマン）インコーポレイテッド 新規抗ｐｄ−１抗体
CN109134655B (zh) * 2018-11-28 2019-02-26 上海复宏汉霖生物技术股份有限公司 一种抗PDGFRα的单克隆抗体及其制备方法和应用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
JPS58166633A (ja) 1982-03-29 1983-10-01 Toshiba Corp 有機溶媒電池用正極
JPS58166634A (ja) 1982-03-29 1983-10-01 Toshiba Corp 有機溶媒電池用正極
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
JPS62170639A (ja) 1986-01-22 1987-07-27 株式会社システムメンテナンス 防蟻板の取付け工法
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0869177B1 (en) 1989-02-09 2008-06-04 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Polyclonal antibody against the human alpha pdgf receptor and use thereof
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
ATE172879T1 (de) 1989-08-09 1998-11-15 Rhomed Inc Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
IE920318A1 (en) 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
DK0584082T3 (da) * 1991-01-31 2000-10-16 Univ California Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5444151A (en) 1992-05-15 1995-08-22 Ludwig Institute For Cancer Research Platelet derived growth factor antagonists
CA2135313A1 (en) 1992-06-18 1994-01-06 Theodore Choi Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69636868T2 (de) 1995-08-29 2007-10-25 Kirin Beer Kabushiki Kaisha Chimäres tier und methode zu dessen herstellung
IT1278764B1 (it) 1995-10-03 1997-11-27 Volta Ind Srl Pila a secco con catodo additivato
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
WO1998035985A1 (en) 1997-02-12 1998-08-20 The Regents Of The University Of Michigan Protein markers for lung cancer and use thereof
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
KR20010075108A (ko) * 1998-09-14 2001-08-09 라즈 외스테르가아드 페데르센 기능적 면역글로불린 수퍼패밀리 단백질을 생산하는 방법
WO2000034784A1 (en) 1998-12-10 2000-06-15 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR100838617B1 (ko) 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
ME00415B (me) 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori
WO2001070979A2 (en) 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
PL359181A1 (en) 2000-07-07 2004-08-23 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
AU2003298799A1 (en) * 2002-12-02 2004-06-23 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
MEP31408A (en) * 2003-07-18 2010-10-10 Abgenix Inc Specific binding agents to hepatocyte growth factor
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005063819A2 (en) * 2003-12-23 2005-07-14 Crucell Holland B.V. Human binding molecule against cd1a
US20080199438A1 (en) 2004-03-16 2008-08-21 Dnavec Research Inc. Methods For Suppressing Tumor Proliferation
ES2452115T3 (es) 2005-06-17 2014-03-31 Imclone Llc Un anticuerpo anti-PDGFRalfa para su uso en el tratamiento de cáncer de huesos metastásico
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Also Published As

Publication number Publication date
HK1128481A1 (en) 2009-10-30
US8697664B2 (en) 2014-04-15
PT2049571E (pt) 2013-03-25
EP2049571B1 (en) 2013-01-02
IL196209A0 (en) 2011-08-01
EP2049571A2 (en) 2009-04-22
PL2049571T3 (pl) 2013-05-31
AR062268A1 (es) 2008-10-29
KR101531422B1 (ko) 2015-06-26
SI2049571T1 (sl) 2013-05-31
CN101558082A (zh) 2009-10-14
TWI503329B (zh) 2015-10-11
EP2420513A1 (en) 2012-02-22
BRPI0715223A2 (pt) 2013-06-18
AU2007348940A1 (en) 2008-09-18
MX2011009563A (es) 2011-11-24
KR20090056969A (ko) 2009-06-03
CA2657898A1 (en) 2008-09-18
JP2010500872A (ja) 2010-01-14
WO2008112003A2 (en) 2008-09-18
MX2009001021A (es) 2009-02-05
CN101558082B (zh) 2013-12-25
ZA200900461B (en) 2010-02-24
US7754859B2 (en) 2010-07-13
NZ575245A (en) 2011-12-22
US20110020360A1 (en) 2011-01-27
US20080089837A1 (en) 2008-04-17
TW200815475A (en) 2008-04-01
IL196209A (en) 2013-03-24
NZ596381A (en) 2013-03-28
IL222833A0 (en) 2012-12-31
DK2049571T3 (da) 2013-04-29
CN103588881A (zh) 2014-02-19
WO2008112003A3 (en) 2008-11-20
ES2402380T3 (es) 2013-05-03
NO20090069L (no) 2009-02-25
CL2007002225A1 (es) 2008-04-18
JP5437804B2 (ja) 2014-03-12
US20090324601A1 (en) 2009-12-31
AU2007348940B2 (en) 2012-06-28
EP2420514A1 (en) 2012-02-22

Similar Documents

Publication Publication Date Title
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
GT201200258A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
GT201200318A (es) Anticuerpos hacia gdf8 humano
ECSP12011694A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2-humana
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
HN2012001846A (es) Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos
BR112012028764A2 (pt) anticor-pos antifgfr2
PA8849001A1 (es) Anticuerpos de c-met
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
CO6450656A2 (es) Anticuerpos anti-tnf-alfa y sus usos
BR112013010544A2 (pt) moléculas de ligação ao egfr e imunoconjugados das mesmas
UA109633C2 (uk) Антитіло людини проти тканинного фактора
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
AR071304A1 (es) Anticuerpos anti cd151 (proteina de membrana de la flia. de las tetraspaninas) utiles para el tratamiento de cancer
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
EA202090372A1 (ru) Универсальные соединения авт и их применение
AR114129A1 (es) ANTICUERPOS TERAPÉUTICOS DIRIGIDOS CONTRA sPLA2-GIB Y SUS USOS
CL2008003525A1 (es) Conjugado de anticuerpo monoclonal humano anti-rg1 o una porcion de union a antigeno del mismo con moleculas asociadas, composicion que lo comprende; metodo in vitro para inhibir el crecimiento de una celula tumoral que expresa rg-1; uso de dicho conjugado para tratar el cancer
CO2023015212A2 (es) Receptores quiméricos dirigidos a adgre2 y/o clec12a y usos de estos
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
AR063011A1 (es) Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico
BR112021024176A2 (pt) Anticorpos anti-angpt2

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170725